225 related articles for article (PubMed ID: 33531368)
1. Early Developmental EEG and Seizure Phenotypes in a Full Gene Deletion of Ubiquitin Protein Ligase E3A Rat Model of Angelman Syndrome.
Born HA; Martinez LA; Levine AT; Harris SE; Mehra S; Lee WL; Dindot SV; Nash KR; Silverman JL; Segal DJ; Weeber EJ; Anderson AE
eNeuro; 2021; 8(2):. PubMed ID: 33531368
[TBL] [Abstract][Full Text] [Related]
2. Abnormal electrophysiological phenotypes and sleep deficits in a mouse model of Angelman Syndrome.
Copping NA; Silverman JL
Mol Autism; 2021 Feb; 12(1):9. PubMed ID: 33549123
[TBL] [Abstract][Full Text] [Related]
3. Strain-dependence of the Angelman Syndrome phenotypes in Ube3a maternal deficiency mice.
Born HA; Dao AT; Levine AT; Lee WL; Mehta NM; Mehra S; Weeber EJ; Anderson AE
Sci Rep; 2017 Aug; 7(1):8451. PubMed ID: 28814801
[TBL] [Abstract][Full Text] [Related]
4. Altered ultrasonic vocalization and impaired learning and memory in Angelman syndrome mouse model with a large maternal deletion from Ube3a to Gabrb3.
Jiang YH; Pan Y; Zhu L; Landa L; Yoo J; Spencer C; Lorenzo I; Brilliant M; Noebels J; Beaudet AL
PLoS One; 2010 Aug; 5(8):e12278. PubMed ID: 20808828
[TBL] [Abstract][Full Text] [Related]
5. Translational outcomes in a full gene deletion of ubiquitin protein ligase E3A rat model of Angelman syndrome.
Berg EL; Pride MC; Petkova SP; Lee RD; Copping NA; Shen Y; Adhikari A; Fenton TA; Pedersen LR; Noakes LS; Nieman BJ; Lerch JP; Harris S; Born HA; Peters MM; Deng P; Cameron DL; Fink KD; Beitnere U; O'Geen H; Anderson AE; Dindot SV; Nash KR; Weeber EJ; Wöhr M; Ellegood J; Segal DJ; Silverman JL
Transl Psychiatry; 2020 Jan; 10(1):39. PubMed ID: 32066685
[TBL] [Abstract][Full Text] [Related]
6. GABAergic Neuron-Specific Loss of Ube3a Causes Angelman Syndrome-Like EEG Abnormalities and Enhances Seizure Susceptibility.
Judson MC; Wallace ML; Sidorov MS; Burette AC; Gu B; van Woerden GM; King IF; Han JE; Zylka MJ; Elgersma Y; Weinberg RJ; Philpot BD
Neuron; 2016 Apr; 90(1):56-69. PubMed ID: 27021170
[TBL] [Abstract][Full Text] [Related]
7. Implications of slow waves and shifting epileptiform discharges in Angelman syndrome.
Yum MS; Lee EH; Kim JH; Ko TS; Yoo HW
Brain Dev; 2013 Mar; 35(3):245-51. PubMed ID: 22704603
[TBL] [Abstract][Full Text] [Related]
8. Generation of a Novel Rat Model of Angelman Syndrome with a Complete Ube3a Gene Deletion.
Dodge A; Peters MM; Greene HE; Dietrick C; Botelho R; Chung D; Willman J; Nenninger AW; Ciarlone S; Kamath SG; Houdek P; Sumová A; Anderson AE; Dindot SV; Berg EL; O'Geen H; Segal DJ; Silverman JL; Weeber EJ; Nash KR
Autism Res; 2020 Mar; 13(3):397-409. PubMed ID: 31961493
[TBL] [Abstract][Full Text] [Related]
9. Flurothyl-induced seizure paradigm revealed higher seizure susceptibility in middle-aged Angelman syndrome mouse model.
Egawa K; Nakakubo S; Kimura S; Goto T; Manabe A; Shiraishi H
Brain Dev; 2021 Apr; 43(4):515-520. PubMed ID: 33408038
[TBL] [Abstract][Full Text] [Related]
10. Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice.
Gu B; Carstens KE; Judson MC; Dalton KA; Rougié M; Clark EP; Dudek SM; Philpot BD
J Clin Invest; 2019 Jan; 129(1):163-168. PubMed ID: 30352049
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-2 does not improve behavioral deficits in mouse and rat models of Angelman Syndrome.
Berg EL; Petkova SP; Born HA; Adhikari A; Anderson AE; Silverman JL
Mol Autism; 2021 Sep; 12(1):59. PubMed ID: 34526125
[TBL] [Abstract][Full Text] [Related]
12. Seizure-like activity in a juvenile Angelman syndrome mouse model is attenuated by reducing Arc expression.
Mandel-Brehm C; Salogiannis J; Dhamne SC; Rotenberg A; Greenberg ME
Proc Natl Acad Sci U S A; 2015 Apr; 112(16):5129-34. PubMed ID: 25848016
[TBL] [Abstract][Full Text] [Related]
13. Delayed loss of UBE3A reduces the expression of Angelman syndrome-associated phenotypes.
Sonzogni M; Hakonen J; Bernabé Kleijn M; Silva-Santos S; Judson MC; Philpot BD; van Woerden GM; Elgersma Y
Mol Autism; 2019; 10():23. PubMed ID: 31143434
[TBL] [Abstract][Full Text] [Related]
14. Lovastatin suppresses hyperexcitability and seizure in Angelman syndrome model.
Chung L; Bey AL; Towers AJ; Cao X; Kim IH; Jiang YH
Neurobiol Dis; 2018 Feb; 110():12-19. PubMed ID: 29097328
[TBL] [Abstract][Full Text] [Related]
15. Sleep disturbances in Ube3a maternal-deficient mice modeling Angelman syndrome.
Colas D; Wagstaff J; Fort P; Salvert D; Sarda N
Neurobiol Dis; 2005 Nov; 20(2):471-8. PubMed ID: 15921919
[TBL] [Abstract][Full Text] [Related]
16. Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome.
Sonzogni M; Zhai P; Mientjes EJ; van Woerden GM; Elgersma Y
Mol Autism; 2020 Sep; 11(1):70. PubMed ID: 32948244
[TBL] [Abstract][Full Text] [Related]
17. A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel
Sonzogni M; Wallaard I; Santos SS; Kingma J; du Mee D; van Woerden GM; Elgersma Y
Mol Autism; 2018; 9():47. PubMed ID: 30220990
[TBL] [Abstract][Full Text] [Related]
18. Excessive Laughter-like Vocalizations, Microcephaly, and Translational Outcomes in the
Berg EL; Jami SA; Petkova SP; Berz A; Fenton TA; Lerch JP; Segal DJ; Gray JA; Ellegood J; Wöhr M; Silverman JL
J Neurosci; 2021 Oct; 41(42):8801-8814. PubMed ID: 34475199
[TBL] [Abstract][Full Text] [Related]
19. A novel UBE3A sequence variant identified in eight related individuals with neurodevelopmental delay, results in a phenotype which does not match the clinical criteria of Angelman syndrome.
Geerts-Haages A; Bossuyt SNV; den Besten I; Bruggenwirth H; van der Burgt I; Yntema HG; Punt AM; Brooks A; Elgersma Y; Distel B; Valstar M
Mol Genet Genomic Med; 2020 Nov; 8(11):e1481. PubMed ID: 32889787
[TBL] [Abstract][Full Text] [Related]
20. Recovery of Angelman syndrome rat deficits with UBE3A protein supplementation.
Dodge A; Morrill NK; Weeber EJ; Nash KR
Mol Cell Neurosci; 2022 May; 120():103724. PubMed ID: 35367589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]